The urokinase plasminogen activator system in breast cancer invasion and metastasis. 2013

Linlin Tang, and Xiuzhen Han
Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, 44, West Wenhua Road, Jinan, Shandong Province 250012, China.

The urokinase plasminogen activator system, which is a serine protease family include urokinase-type plasminogen activator (uPA), the uPA receptor and plasminogen activator inhibitors (PAIs). uPA catalyzes the transformation of plasminogen to its active form plasmin, which is able to degrade the extracellular matrix (ECM) and basement membranes, directly or indirectly through activating pro-matrix metalloproteinases (pro-MMPs), promoting cancer cell metastasis and invasion. Both uPA and PAI-1 are poor prognosis markers in primary breast cancer. Evidence has been presented that the uPA system facilitates breast cancer metastasis by several different mechanisms, such as the Ras-ERK pathway and p38 MAPK pathway. This review focuses on uPA system, summarizes their biological effects, highlights the molecular mechanism and pathway, and discusses the role of uPA system in the prevention and treatment of human breast cancers.

UI MeSH Term Description Entries
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator
D015849 Plasminogen Inactivators Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators. Plasminogen Activator Inhibitor,Plasminogen Activator Inhibitors,Endothelial Plasminogen Activator Inhibitors,Placental Plasminogen Activator Inhibitors,Plasminogen Activator Inhibitors, Endothelial,Plasminogen Activator Inhibitors, Placental,Activator Inhibitor, Plasminogen,Inactivators, Plasminogen,Inhibitor, Plasminogen Activator,Inhibitors, Plasminogen Activator
D055293 Receptors, Urokinase Plasminogen Activator An extracellular receptor specific for UROKINASE-TYPE PLASMINOGEN ACTIVATOR. It is attached to the cell membrane via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and plays a role in the co-localization of urokinase-type plasminogen activator with PLASMINOGEN. Antigens, CD87,Urokinase Plasminogen Activator Receptor,Urokinase Type Plasminogen Activator Receptor,Urokinase-Type Plasminogen Activator Receptor,CD87 Antigen,Plasminogen Activator Receptor, Urokinase Type,Plasminogen Activator, Urokinase Receptor,Plasminogen Activator, Urokinase Receptors,Receptor, Pro-Urokinase,Receptor, Urokinase Plasminogen Activator,U-PA Receptor,Upar Receptor,Urokinase Plasminogen Activator Receptors,Urokinase-Type Plasminogen Activator Receptors,Antigen, CD87,CD87 Antigens,Pro-Urokinase Receptor,Receptor, Pro Urokinase,Receptor, U-PA,Receptor, Upar,U PA Receptor,Urokinase Type Plasminogen Activator Receptors

Related Publications

Linlin Tang, and Xiuzhen Han
May 1995, International journal of cancer,
Linlin Tang, and Xiuzhen Han
January 2001, Cancer metastasis reviews,
Linlin Tang, and Xiuzhen Han
July 2005, Oncology reports,
Linlin Tang, and Xiuzhen Han
July 1997, International journal of cancer,
Linlin Tang, and Xiuzhen Han
June 1995, Pathology, research and practice,
Linlin Tang, and Xiuzhen Han
January 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
Linlin Tang, and Xiuzhen Han
January 1990, Lancet (London, England),
Linlin Tang, and Xiuzhen Han
January 2012, World journal of gastroenterology,
Copied contents to your clipboard!